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Abstract
Background: Angiogenesis plays an important role in the development of multiple myeloma (MM). The interaction
between MM cells and the bone marrow microenvironment stimulates the proliferation and migration of
endothelial progenitor cells (EPCs). Vascular endothelial growth factor (VEGF) contributes to the formation of new
blood vessels by actively recruiting circulating EPCs. The production of proangiogenic and antiangiogenic factors is
also dysregulated in MM. Platelet factor 4 (PF4) is a potent angiostatic cytokine that inhibits angiogenesis and
tumor growth in several animal models.
Methods: In this study, we stably transfected human myeloma cell lines with the PF4 gene or the sequence
encoding its more potent p17-70 peptide and investigated the effects of PF4 and p17-70 on angiogenesis and
tumor growth in vitro and in a SCID-rab myeloma model.
Results: PF4 and p17-70 significantly attenuated VEGF production, both in vitro and in vivo. In a migration study
using a Transwell system, PF4 or p17-70 markedly suppressed the migration of co-cultured human endothelial
progenitor cells. PF4 or p17-70 also caused a significant reduction in microvessel densities in myeloma xenografts
and markedly reduced the tumor volume in the SCID mice. Kaplan-Meier analysis demonstrated that PF4 and
p17-70 significantly extended the overall survival of SCID mice bearing human myeloma xenografts.
Conclusions: Our findings indicate that PF4 or p17-70 could be valuable in combating multiple myeloma by
disrupting tumor angiogenesis.
Background
Multiple myeloma (MM) is a plasma cell neoplasm
characterized by skeletal destruction, renal failure, ane-
mia, and hypercalcemia, and is the second most com-
mon hematological neoplasm after lymphoma [1,2].
Novel agents such as the proteasome inhibitor bortezo-
mib, thalidomide, and lenalidomide have so far only
produced a modest improvement in the therapeutic out-
comes of MM patients [3] and it remains an incurable
disease.
The therapeutic effect of thalidomide is partly attribu-
ted to its antiangiogenic action on MM cells [4]. Bone
marrow angiogenesis occurs in MM patients and corre-
lates with the treatment response and survival [5].
Angiogenesis involves the development of blood vessels
of capillary origin, a process tightly controlled by
proangiogenic factors such as fibroblast growth factor 2
(FGF2) and vascular endothelial growth factor (VEGF).
Human endothelial progenitor cells (EPCs) contribute to
this neovascularization [6], and consequently, the inhibi-
tion of EPC recruitment can lead to the suppression of
tumor angiogenesis and hence the inhibition of tumor
growth, offering a promising therapeutic target [7,8].
The chemokine platelet factor 4 (PF4) is a 70-residue
polypeptide with pleiotropic biological effects. It is
released from platelet a-granules during platelet aggre-
gation [9,10]. As well as being synthesized in platelets or
megakaryocytes, is also produced in other cell types,
including monocytes, T-cells, and neutrophils [11]. PF4
exerts potent angiostatic effects by inhibiting endothelial
cell proliferation, and this effect is localized to the
amino acid residues 17-70 of the molecule [12,13]. PF4
and p17-70 suppress angiogenesis by inhibiting proan-
giogenic factors such as FGF2 [14-17]. PF4 also inhibits
the function of VEGF by disrupting the binding of
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induced intracellular signaling cascade [19].
Aberrant angiogenesis arising from the dysregulation
of the production of proangiogenic and antiangiogenic
factors is observed in MM patients. Our genomic analy-
sis of human myeloma cells showed that the PF4 gene is
frequently silenced by promoter hypermethylation,
which could contribute to the aberrant angiogenesis in
MM [20]. Therefore, we hypothesized that the overex-
pression of the PF4 gene or p17-70 in MM cells would
inhibit the growth of myeloma by inhibiting the func-
tions of proangiogenic factors such as FGF2 and VEGF.
In this study, we investigated the effects of the overex-
pression of the PF4 gene or p17-70 in MM cells on
VEGF production and also examined its effects on
angiogenesis in cell lines and a mouse xenograft model.
Methods
Cell lines
The myeloma-derived cell lines U266, RPMI8226, and
LP-1 were purchased from the American Type Culture
Collection (Manassas, VA) and cultured in RPMI-1640
medium containing 10% fetal bovine serum (FBS), peni-
cillin (10 IU/ml) and streptomycin (100 μg/ml) (Invitro-
gen, Carlsbad, CA) at 37°C with 5% CO2. HEK 293T
cells were also grown in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% FBS and
1% penicillin/streptomycin under the same conditions.
Human EPCs were cultured and maintained as pre-
viously described [21].
Lentiviral Transfection
T h ee n t i r eo p e nr e a d i n gf r a m eo fPF4 (NCBI reference
sequence: NM_002619) was amplified using the PF4 pri-
mers: forward 5"-GCGAATTCGCCACCATGGAAGCG-
GAAGAAGATGGGG-3” and reverse 5"-CCGCTCGAG
TTAACTCTCCAAAAGTTTC-3”. The sequence encod-
ing p17-70 was amplified with primers: forward 5"-
GCGAATTCGCCACCATGACCTCCCAGGTCCGTCC-
CAG-3” and reverse 5’- CCGCTCGAGTTAACTCTC-
CAAAAGTTTC-3”. The PCR was performed in a 50 μl
reaction containing 5 μlo f1 0×E xb u f f e r ,2 . 5m M
dNTPs, 10 μL of each primer, 0.25 μLo fE xTaq DNA
polymerase (Takara, Millipore), and 1 μl of DNA tem-
plate. To amplify the PF4 gene or p17-70, the PCR was
run for 35 cycles of 94°C for 1 min, at 60°C for 1 min,
and at 72°C for 1 min, followed by a final extension at
72°C for 10 min. The PCR products were gel purified
and the PF4 or p17-70 cDNA was inserted into the
EcoRI/XhoI sites of the vector pIRES2-ZsGreen1 (BD
Biosciences) to generate two new vectors, pPF4-IRES2-
ZsGreen1 and psPF4-IRES2-ZsGreen1. The two plas-
mids were confirmed by sequencing (Sangon, Shanghai,
China). We next transfected HEK 293T cells with the
expression vectors pPF4-IRES2-ZsGreen1 or psPF4-
IRES2-ZsGreen1 and the packaging plasmid mix, as
instructed by the manufacturer (Clontech Laboratories,
Mountain View, CA). After incubation for 36-72 hours,
the lentiviral vectors were harvested from the superna-
tants using the QuickTiter™ Lentivirus Concentration
and Purification Kit (Cell Biolabs, San Diego, CA). The
lentiviral transfections were performed at a minimum
effective multiplicity of infection of 20. The efficiency of
transfection was estimated by counting the percentage
of green fluorescent protein (GFP)-positive cells 48 h
after transfection. The transfected cell lines U266,
RPMI8226, and LP-1 were treated with G418 (Sigma, St
L o u i s ,M O )a ti n c r e a s i n gc o n c e n t r a t i o n sf r o m2 0 0t o
1,000 μg/mL for 6 days, and the stable cell lines were
then screened using the limited dilution method, as
described previously [22].
Immunoblotting studies and enzyme-linked
immunosorbent assay (ELISA)
The production of PF4 and p17-70 in the U266,
RPMI8226, and LP-1 cell lines, and the appropriate con-
trols, was examined by immunoblotting studies according
to a previous report [23,24], The antibodies used were
anti-PF4 antibody (Cell Signaling, Danvers, MA) and
anti-b-actin antibody (Santa Cruz Biotechnology, Santa
Cruz, CA). The protein contents were determined with
the Bradford method and equal amounts of cellular
lysates were resolved by gradient (4-12%) sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE;
Bio-Rad, Hercules, CA). The VEGF levels in the superna-
tants of the cell lines and controls were measured with a
Quantikine VEGF ELISA Kit (R&D Systems, Minneapo-
lis, MN), according to the manufacturer’s protocol.
Coculture of MM cells with human EPCs
Mononuclear cells were isolated from human EDTA-blood
by centrifugation on Ficoll-Paque Plus gradient (Amersham
Biosciences). The isolated cells were suspended in Medium
199 with 20% New-Born Calf Serum (NBCS), 30 ng/ml
recombinated human vascular endothelial growth factor
(rh-VEGF) and 6 ng/ml recombinated human basic fibro-
blast growth factor (rh-b-FGF), as previously described
[25]. Human EPCs were washed three times with phos-
phate-buffered saline to remove any loosely attached cells.
The adherent cells (1 × 10
5 cells) were then harvested after
synchronization for 24 h with serum-free medium and
cocultured with the appropriate myeloma cell lines (1 ×
10
5 cells) in RPMI-1640 medium containing 10% FBS in a
Transwell system (8 μm, Costar, Cambridge, MA). Migra-
tion assay was performed as previous description [26].
Cells were dispersed onto filters, and were then challenged
by the addition of 600 μl of a chemoattractant solution
composed of conditioned media, and 50 ng/ml rh-VEGF
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Migration was allowed to proceed for 24 h at 37°C under
hypoxia. Cells remaining attached to the upper surface of
the filters were carefully removed with cotton swabs. Cells
that had migrated to the lower surface of the filters were
f i x e dw i t h1 0 %n e u t r a lb u f f e r e df o r m a l i n ,s t a i n e dw i t h0 . 1 %
crystal violet/20% MeOH, and counted. The average num-
ber of migrating cells per field was assessed by counting at
least four random fields per filter.
Proliferations of human EPCs
The EPC proliferation was determined by colorimetric
3-(4, 5-dimethylthiazol-2-yl)-2,5 -diphenyltetrazollium
bromide (MTT) assay. MTT (Sigma) was dissolved in
phosphate-buffered saline (PBS) at 5 mg/ml and used to
measure cell proliferation. Five thousand colony-derived
cells were cultured in 96-well culture plate (200 μl/well).
The cells were resuspended in RPMI-1640 containing
10% FBS medium were divided into groups according to
the study design and were cultured for 0, 4, 8,12, and 24
hours. And then serum-free medium (180 μl) with MTT
(20 μl, 5 mg/ml) was added and incubated for another 4
h. The supernatant was discarded by aspiration and
EPCs preparation was shaken with 150 μLD M S Of o r
10 min prior to the measurement of OD value at 490
nm on a micro oscillating device.
Terminal-deoxynucleotidyl-transferase-mediated biotin-
dUTP nick end labeling (TUNEL) and annexin V/propidium
iodide staining
Human EPCs were collected, applied to prepared cytospin
slides (10
5 cells/slide), and fixed in 10% phosphate-buf-
fered formalin for 20 min in freshly prepared 4% parafor-
maldehyde. The TUNEL assay was performed using the
Klenow FragEL™ DNA Fragmentation Detection Kit (Cal-
biochem, Darmstadt, Germany) according to the manufac-
turer’s instructions. The EPCs cocultured with myeloma
cells for 48 h were collected and stained with an annexin
V-propidium iodide (PI) detection kit for apoptosis (Caltag
Laboratories, Burlingame, CA), as instructed by the manu-
facturer, and analyzed by flow cytometry on a FACScan
flow cytometer (Becton Dickinson, San Jose, CA). The
results are expressed as the percentage of apoptotic cells
that stained positively for annexin V. The adherent EPCs
were also stained for annexin V-propidium iodide and the
total number of apoptotic cells was counted under a Zeiss
AX10 Observer A1 microscope (Delta Optical Instru-
ments, Thornwood, NY).
SCID-rab myeloma model
SCID mice, 6-8 weeks old and weighing 18-20 g, were
used to establish the SCID-rab myeloma model [27].
Four-week-old rabbits were anesthetized with phenobar-
bital sodium and killed by cervical dislocation. Their
tibiae were removed and cut into bone blocks of 5 × 5
×1 0m m
3, which were then inserted subcutaneously
through a 5 mm incision onto the ventral surfaces of
the SCID mice. Four weeks was allowed for the engraft-
ment of the bones to occur. For each mouse, 3-5 × 10
6
U266, RPMI8226, or LP-1 cells stably transfected with
the PF4 or p17-70 cDNA or the control plasmid were
injected directly into the implanted rabbit tibiae. Eight
SCID mice were injected with each of the appropriate
tumor cells. The mice were bled from the tail vein every
2 weeks and changes in the levels of circulating human
immunoglobulin light chain proteins and VEGF were
measured by ELISA. The tumor volume was calculated
with the following formula: volume = (4/3) × 3.14 ×
(long diameter/2) (short diameter/2) (long diameter +
short diameter)/4. The growth of the tumor xenografts
in the SCID mice was examined by normal and X-ray
photography 12 weeks after the inoculation of the
tumor cells. After the animals were killed, the gross
appearance of the tumors was examined and tissue sec-
tions were prepared from the tibiae bearing human
myeloma xenografts for hematoxylin-eosin staining and
for immunohistochemical staining with antibody direc-
ted against CD31 (Santa Cruz Biotechnology). The
microvessel density (MVD) within the tumor was deter-
mined by immunohistochemistry for CD31.
Statistical analysis
Each experiment was performed independently at least
three times. The data were plotted as mean ± SD and
analyzed for statistical significance between groups with
the use of ANOVA followed by post hoc Student-New-
man-Keuls test. A two-tailed paired Student’s t test was
used to compare significant difference between groups
in human immunoglobulin light chain protein levels and
human VEGF levels. For the in vivo study, the data
were plotted as mean ± SD and analyzed for statistical
significance with the use of repeated measures ANOVA.
A P value of less than 0.05 was considered statistically
significant. The survival rates were compared using the
Kaplan-Meier method and the log-rank test.
Results
PF4 and p17-70 attenuate VEGF production in myeloma
cells in vitro
We generated stable human myeloma cell lines (U266,
RPMI8226, and LP-1) expressing PF4 or p17-70. RT-
PCR analysis revealed that the stable U266 cell line
expressed the appropriately sized PF4 or p17-70 pro-
ducts (Figure 1A). The production of the U266,
RPMI8226, and LP-1 cells showed that PF4 or p17-70
was effectively produced from these cell lines transfected
with either the PF4 gene or sequence encoding p17-70,
whereas neither of them was detected in the control
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of the effects of PF4 and p17-70 on the expression of
VEGF, we found that the levels of VEGF in the superna-
tants of the U266, RPMI8226, and LP-1 cells stably expres-
sing the PF4 gene were significant reduced to 160.36 ±
8.80 pg/ml, 147.61 ± 5.15 pg/ml, and 167.92 ± 10.28 pg/
ml, respectively, compared with their control counterparts
U266-neo 663.58 ± 142.16 pg/ml, RPMI8226-neo 848.61
± 216.15 pg/ml, and LP-1-neo 701.73 ± 192.81 pg/ml (all
P < 0.01; Figure 1C). Similar results were observed for
p17-70, and the levels of VEGF in the supernatants of the
U266, RPMI8226, and LP-1 cells stably expressing the
p17-70 gene fragment were apparently reduced to 98.25 ±
9.65 pg/ml, 86.73 ± 4.81 pg/ml, and 109.32 ± 5.28 pg/ml,
respectively (all P < 0.01).
Activation in human EPCs by PF4 or p17-70
We examined the effects of PF4 and p17-70 on the migra-
tory capacity of activated human EPCs. EPCs cocultured
with U266, RPMI8226, or LP-1 myeloma cells stably
expressing PF4 were significantly reduced to 70%, 61%, and
67%, respectively, whereas those expressing the p17-70
fragment were reduced to 87%, 85% and 77%, respectively,
compared with the control cells (all P < 0.05; Figure 2A).
Figure 1 PF4 and p17-70 attenuate VEGF production in myeloma cells in vitro. (A) Identification of the expression and integration of
foreign genes (A: 1-2): RT-PCR analysis of RNA in U266 cells transfected with different retroviruses. M: DNA size marker; lane 1: p17-70-infected
U266 cells (150 bp); lane 2: PF4-infected U266 cells (170 bp). (B) Western blotting assay of selected MM cells. Control groups: U266-neo,
RPMI8226-neo, and LP-1-neo; p17-70 groups: U266-p17-70, RPMI8226-p17-70, and LP-1-p17-70. (C) VEGF levels in the supernatants of three sorts
of MM cells. There were significant differences in the VEGF levels in the supernatants of the U266 cells among the groups (PF4: 160.36 ± 8.80
pg/ml, p17-70: 98.25 ± 9.65 pg/ml, U266-neo: 663.58 ± 142.16 pg/ml, both of P < 0.01). There were significant differences in the VEGF levels in
the supernatants of the RPMI8226 cells among the groups (PF4: 147.61 ± 5.15 pg/ml, p17-70: 86.73 ± 4.81 pg/ml, RPMI8226-neo: 848.61 ± 216.15
pg/ml both of P < 0.01). There were significant differences in the VEGF levels in the supernatants of the LP-1 cells among the groups (PF4:
167.92 ± 10.28 pg/ml, p17-70: 109.32 ± 5.28 pg/ml pg/ml, LP-1-neo: 701.73 ± 192.81 pg/ml both of P < 0.01). Figures represents the three
independent experiments done in triplicate (**, P < 0.01).
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fragment on cell proliferation, and showed that both of
them expressed in U266, RPMI8226, and LP-1 myeloma
cells markedly inhibited the proliferation of human EPCs
to 67%, 73%, 58%, and 49%, 56%, 42%, respectively (all P <
0.05; Figure 2B). However, no significant difference was
observed in the apoptosis of the cell lines and the control
cells (all P > 0.05; Figure 2C).
PF4 and p17-70 attenuated the growth of myeloma in
SCID-rab mice
We established a SCID-rab model of myeloma. Figure 3
shows in photographs and X-ray photographs that sub-
stantial tumors developed after the 12 weeks after the
SCID-rab mice were inoculated with U266 cells. Similar
results were observed in the SCID-rab mice inoculated
with RPMI8226 or LP-1 cells (data not shown). The
control mice had tumor sizes of 151.3 ± 14.5 mm
3
-(Figure 3A), 163.5 ± 16.4 mm
3, and 200.3 ± 16.7 mm
3
after inoculation with U266, RPMI8226, and LP-1,
respectively. In contrast, the tumor sizes in the SCID-
rab mice inoculated with myeloma cells stably expres-
sing the PF4 gene was significantly smaller (102.3 ±
19.8 mm
3, 118.2 ± 17.9 mm
3, and 144.9 ± 15.6 mm
3 for
U266 [Figure 3B], RPMI8226, and LP-1, respectively;
P < 0.05) and in those inoculated with myeloma cells
stably expressing the p17-70 fragment (76.6=± 7.9 mm
3,
85.4 ± 8.2 mm
3, and 87.1 ± 9.6 mm
3 for U266 [Figure 3C],
RPMI8226, and LP-1 cells, respectively; P <0 . 0 5 ) ,s u g g e s t -
ing that PF4 and p17-70 attenuated the growth of the
myelomas in the SCID-rab mice.
PF4 and p17-70 suppressed angiogenesis of myelomas in
SCID-rab mice
We further assessed the MVD in tumor sections
stained with anti-CD31 antibody. The blood vessel
densities of the tumors from the U266-neo (30 ± 3
vessels/field) (Figure 3D), which was higher than
U266-PF4 (15 ± 2 vessels/field) (P = 0.036, Figure 3E).
The RPMI8226-neo (36 ± 4 vessels/field) was higher
than RPMI8226-PF4 (17 ± 3 vessels/field) (P =0 . 0 3 9 ) ,
while LP-1-neo (28 ± 3 vessels/field) groups were
higher thanthe blood vessel densities of the LP-1-PF4
(16 ± 3 vessels/field) groups too (P = 0.041). The simi-
lar results were observed among p17-70 treated with
U266 (Figure 3F), RPMI8226, and LP-1 myeloma cells
when compared with control group (P <0 . 0 5i na l l
three groups, data not shown).
Figure 2 The EPCs properties in three sorts of MM cells. (A) The migration capacities of EPCs detected by transwell migration (P = 0.024). (B)
The proliferation capacities of EPCs determined by MTT assay (P = 0.019). (C) The apoptosis capacities of EPCs used annexin V/PI staining assay (P
= 0.34). Figures represents the three independent experiments done in triplicate (*, P < 0.05).
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chain protein levels in myeloma cells of SCID-rab mice
We then determined whether the reduced tumor size in
the SCID-rab mice inoculated with myeloma cells stably
expressing PF4 or p17-70 was associated with a reduc-
tion in the production of the human immunoglobulin
light chain. The serum levels of human immunoglobulin
light chain in these SCID-rab mice were significantly
reduced compared with those in the control cells. In
U266 cells, the serum levels of human immunoglobulin
light chain protein levels in the SCID mice bearing
human myeloma xenografts stably expressing PF4 (346.3
± 45.4 pg/ml) or the p17-70 gene fragment (327.8 ±
34.2 pg/ml) compared to control (823.2 ± 53.7 pg/ml)
from U266 cells at 16 weeks, that the experiments
groups in RPMI8226 and LP-1 cells were observed the
similar results [RPMI8226: PF4 (325.6 ± 47.3 pg/ml);
p17-70 (338.0 ± 36.1 pg/ml); RPMI8226-neo (778.7 ±
55.1), LP-1: PF4 (334.6 ± 53.1 pg/ml); p17-70 (289.0 ±
32.7 pg/ml); LP-1-neo (819.7 ± 56.3 pg/ml)] (P < 0.01 in
all three groups; Figure 4).
PF4 and p17-70 inhibited VEGF production of myeloma in
SCID-rab mice
Because local blood vessel formation is associated with
the growth and metastasis of tumors, we investigated
whether PF4 and p17-70 inhibited the production of
VEGF in SCID mice bearing human myeloma xeno-
grafts. We found that PF4 or p17-70 caused a signifi-
cant reduction in the serum levels of VEGF in the SCID
mice bearing human myeloma xenografts stably expres-
sing PF4 (191.1 ± 26.5 pg/ml) or the p17-70 gene frag-
ment (183.7 ± 12.6 pg/ml) compared to control (468.1
± 42.8 pg/ml) from U266 cells at 12 weeks, that the
experiments groups in RPMI8226 and LP-1 cells were
observed the similar results, which were the serum
levels of VEGF in RPMI8226 expressing PF4 (155.3 ±
16.5 pg/ml), the p17-70 gene fragment (130.5 ± 18.3
pg/ml) compared to control (410.7 ± 30.8 pg/ml), and
in LP-1 expressing PF4 (155.3 ± 16.5 pg/ml), the p17-70
gene fragment (196.3 ± 20.7 pg/ml) compared to con-
trol (436.3 ± 34.5 pg/ml) (P <0 . 0 1i na l lt h r e eg r o u p s ;
Figure 5).
Figure 3 Photographs of representative tumors and immunostaining of representative tumors. Photographs of representative tumors
from the U266-neo (151.3 ± 14.5 mm
3) (A), U266-PF4 (102.3 ± 19.8 mm
3) (B), and U266-p17-70 (76.6 ± 7.9 mm
3) groups (C). Immunostained
tumor tissue sections from representative tumors from the U266-neo (D), U266-PF4 (E), and U266-p17-70 groups (F) are shown. Micrographs
were taken at a magnification of 400×, except the section from a U266-p17-70 mouse, which was magnified 200 ×, which was processed by
GIMP2 software.
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bearing human myeloma xenografts
We also examined the effects of PF4 and p17-70 on the
overall survival (OS) of SCID mice bearing human U266
myeloma xenografts. All the SCID mice survived longer
than 14 weeks, whereas only one SCID mouse from the
control group was dead at 14 weeks. Most importantly,
animals bearing a U266 xenograft stably expressing PF4
or the p17-70 fragment (median OS of 18 or 20 weeks,
respectively) survived significantly longer than the con-
trol animals (P = 0.004; Figure 6), further highlighting
the potential of PF4 or the p17-70 fragment expression
effects. The similar results were observed of SCID mice
bearing human RPMI8226 or LP-1 myeloma xenografts
(data not shown).
Discussion
Tumors recruit neighboring blood vessels and vascular
endothelial cells to support their own malignant growth.
In the process, tumor cells secrete trophic angiogenic
molecules, such as VEGF, that induce the proliferation
and migration of EPCs into the tumor. Angiogenesis
plays an important role in the development of MM [28].
The interaction between MM cells and the bone mar-
row microenvironment stimulates the proliferation and
migration of endothelial cells. VEGF contributes to the
formation of new blood vessels by actively recruiting cir-
culating EPCs. The production of proangiogenic and
antiangiogenic factors is also dysregulated in MM. In a
previous study, we showed that the promoter region of
the PF4 gene, whose product has potent angiostatic
effects, is frequently hypermethylated [20], which could
tip the balance between the pro- and antiangiogenic fac-
tors in favor of aberrant angiogenesis in MM. We have
shown here that the overexpression of PF4 or p17-70 in
MM cells attenuated the production of VEGF from
these cells in vitro. We also found significantly reduced
serum levels of VEGF in the SCID-rab model of mye-
loma expressing PF4 or the p17-70 fragment. Other
investigators have shown that PF4 inhibits the function
Figure 4 Human immunoglobulin light chain protein levels in the sera of mice after treated with three sorts of MM cells. There were
significant differences in the human immunoglobulin light chain protein levels in the sera of the mice in the three groups treated with three
sorts of MM cells (all P < 0.01). (A) Light chain levels of SCID-rab MM mice with tumors derived from U266 cells at 16 weeks [PF4 (346.3 ± 45.4
pg/ml); p17-70 (327.8 ± 34.2 pg/ml); U266-neo (823.2 ± 53.7 pg/ml)]. (B) Light chain levels of SCID-rab MM mice with tumors derived from
RPMI8226 cells at 16 weeks [RPMI8226: PF4 (325.6 ± 47.3 pg/ml); p17-70 gene fragment (338.0 ± 36.1 pg/ml); RPMI8226-neo (778.7 ± 55.1)]. (C)
Light chain levels of SCID-rab MM mice with tumors derived from LP-1 cells at 16 weeks [PF4 (334.6 ± 53.1 pg/ml); p17-70 (289.0 ± 32.7 pg/ml);
LP-1-neo (819.7 ± 56.3 pg/ml)].
Yang et al. BMC Cancer 2011, 11:261
http://www.biomedcentral.com/1471-2407/11/261
Page 7 of 10of VEGF by disrupting the binding of VEGF to its
receptor [18] and disrupting the VEGF-induced intracel-
lular signaling cascade [19]. Our findings suggest that
PF4 or the p17-70 fragment also suppresses VEGF func-
tion by attenuating the production of this potent proan-
giogenic factor. However, the exact mechanism by
which PF4 exerts its effect on VEGF levels remains to
be identified.
The recruitment of circulating EPCs to a tumor site,
which leads to aberrant angiogenesis in the tumor, contri-
butes to the tumor’s malignant growth and metastasis.
PF4 inhibits the functions of two potent proangiogenic
factors, FGF and VEGF, that actively recruit circulating
endothelial cells to form new blood vessels in the tumor
[18,19]. We found that the attenuated production of
VEGF in myeloma cells overexpressing PF4 or p17-70 was
associated with the reduced migration of EPCs in vitro.
Our analysis of MVD in the SCID-rab model of myeloma
further showed that myelomas overexpressing PF4 or p17-
70 exhibited markedly reduced angiogenesis. These find-
ings demonstrate that PF4 exerts its angiostatic effects
both in vitro and in vivo. PF4 suppresses tumor angiogen-
esis by attenuating VEGF production and causing the
impaired migration of EPCs to the tumor site.
Tumor growth depends on angiogenesis. The viral-vec-
tor-mediated transfection of the PF4 gene suppressed
endothelial cell proliferation and angiogenesis in a mouse
xenograft model with glioma, and this was associated with
the prolonged survival of the tumor-bearing mice [29]. The
tumor-growth-inhibitory effect of PF4 has also been
observed in an animal xenograft model of lung cancer [30],
and in glioblastoma in an orthotopic human glioblastoma
model [31]. No previous report of the effect of PF4 on MM
has been available. We established a SCID-rab model of
myeloma [27] by inoculating human myeloma cells directly
into rabbit tibiae already implanted subcutaneously in
Figure 5 Human VEGF levels in the sera of mice. (A) SCID-rab MM mice with tumors derived from U266 cells. There were significant
differences in VEGF levels in the sera of mice among the groups [PF4 (191.1 ± 26.5 pg/ml); p17-70 (183.7 ± 12.6 pg/ml); U266-neo (468.1 ± 42.8
pg/ml), P = 0.002]. (B) SCID-rab MM mice with tumors derived from RPMI8226 cells. There were significant differences in VEGF levels in the sera
of mice among the groups [PF4 (155.3 ± 16.5 pg/ml); p17-70 (130.5 ± 18.3 pg/ml); RPMI8226-neo (410.7 ± 30.8 pg/ml), P = 0.001]. (C) SCID-rab
MM mice with tumors derived from LP-1 cells. There were significant differences in VEGF levels in the sera of mice among the groups [PF4
(155.3 ± 16.5 pg/ml); p17-70 (196.3 ± 20.7 pg/ml); LP-1-neo (436.3 ± 34.5 pg/ml),P= 0.001]
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Page 8 of 10SCID mice. We showed that the transfection of the PF4
gene or a sequence encoding p17-70 suppressed the
growth of the human myeloma cells in the SCID mice,
causing a marked reduction in the tumor volume. Kaplan-
Meier analysis further demonstrated that PF4 and p17-70
significantly extended the OS of SICD mice bearing human
myeloma xenografts.
PF4 is one of the first cytokines discovered to have
antiangiogenic activity in ex vivo systems, and its peptide
also displays strong antiangiogenic activity [12]. PF4
exerts pleiotropic biological effects, and our study and
studies by other investigators strongly indicate that its
tumor-growth-inhibitory effect is closely associated with
its antiangiogenic activity. MM remains a devastating
disease with a dismal outcome, despite improved thera-
pies with novel therapeutic agents. Effectively targeting
angiogenesis in MM offers a promising approach to
combat the disease. Further studies of PF4 and p17-70
are required to explore the therapeutic potential of this
angiostatic agent.
Conclusions
Our findings indicate that PF4 or p17-70 could be valu-
able in combating multiple myeloma by disrupting
tumor angiogenesis.
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